Surface Oncology: Surges on partnering with Merck for cancer therapy

Surface Oncology

20/05/2020 12:44

** Shares of drug developer  SURF.O  surge 57% to $4.18
premarket
    ** SURF top pct. gainer across U.S. exchanges - set to open
at 1-yr high
    ** Company, through a subsidiary, enters into a clinical
trial partnership with Merck & Co  MRK.N  to test its cancer
therapy, SRF617, with Keytruda  urn:newsml:reuters.com:*:nGNX9h9ZM7
    ** The combination will be tested in patients with solid
tumors, focusing specially on gastric cancer and those who have
developed resistance to checkpoint inhibition - SURF
    ** Stock up 41.5% YTD, as of last close

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))